Celgene Seeks To Expand Revlimid In Leukemia, Non-Hodgkin’s Lymphoma In The Near Term
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm also looking at combining lenalidomide with Genentech’s Rituxan.
You may also be interested in...
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Celgene Will Take Barr To Court Over Thalomid Patents
Barr filed an ANDA for thalidomide for erythema nodosum leprosum, although Celgene markets the drug more broadly for multiple myeloma.